Drug Type Small molecule drug |
Synonyms Vecabrutinib (USAN/INN), Vecabrutinib succinate, BIIB-062 + [6] |
Target |
Mechanism BTK C481S inhibitors(Bruton Tyrosine Kinase C481S inhibitors), ITK inhibitors(Tyrosine-protein kinase ITK/TSK inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H24ClF4N7O2 |
InChIKeyQLRRJMOBVVGXEJ-XHSDSOJGSA-N |
CAS Registry1510829-06-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11428 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | US | 29 Nov 2018 | |
Neoplasms | Phase 2 | US | 29 Nov 2018 | |
Chronic Lymphocytic Leukemia | Phase 2 | US | 28 Apr 2017 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | US | 28 Apr 2017 | |
Follicular Lymphoma | Phase 2 | US | 28 Apr 2017 | |
Mantle-Cell Lymphoma | Phase 2 | US | 28 Apr 2017 | |
Marginal Zone B-Cell Lymphoma | Phase 2 | US | 28 Apr 2017 | |
Small Lymphocytic Lymphoma | Phase 2 | US | 28 Apr 2017 | |
Waldenstrom Macroglobulinemia | Phase 2 | US | 28 Apr 2017 |